J&J’s Erda-iDRS Shows Promising Early Results in Bladder Cancer

Johnson & Johnson has reported positive Phase I data for its investigational intravesical system, Erda-iDRS (erdafitinib), in patients with Non–Muscle-Invasive Bladder Cancer with FGFR alterations.

The study met its primary safety endpoint and demonstrated durable complete responses in intermediate-risk patients, along with encouraging recurrence-free outcomes in high-risk cases. Results were presented at the European Association of Urology Annual Meeting 2026.

Erda-iDRS delivers erdafitinib directly into the bladder over three months, enabling localized treatment while minimizing systemic exposure. In intermediate-risk patients, the complete response rate reached 89%, with a median duration of 18 months. High-risk patients showed a median recurrence-free survival of 20 months.

The therapy was generally well tolerated, with mostly local adverse events. These findings highlight the potential of targeted, localized treatment approaches in earlier-stage bladder cancer.

16-03-2026